2025 China Attention-Deficit Hyperactivity Disorder Revenue Opportunities Report
Description
The 2025 China Attention-Deficit Hyperactivity Disorder Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Attention-Deficit Hyperactivity Disorder by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Attention-Deficit Hyperactivity Disorder (ADHD) market in China are Shanghai Fosun Pharmaceutical, Huadong Medicine, Adlon Therapeutics, and Ignis Therapeutics. Shanghai Fosun Pharmaceutical, Huadong Medicine, and Adlon Therapeutics are identified as key domestic players involved in ADHD therapeutics, leveraging China's sizable young population and increasing ADHD awareness to expand their market presence. Ignis Therapeutics has notably acquired exclusive licensing rights for NeuroSigma's Monarch eTNS System in China, introducing advanced bioelectronic non-invasive therapies for ADHD, which supplements traditional pharmacological treatments and enhances the therapeutic options available in the Chinese market.
In addition to these domestic companies, several multinational pharmaceutical corporations also have a significant presence in the ADHD market in China, including Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical, and Johnson & Johnson. These firms provide a variety of stimulant and non-stimulant medications for ADHD, contributing to a competitive and rapidly growing market projected to reach nearly $4.73 billion by 2030. The market growth is driven by increased diagnosis rates, government support, advanced therapies, and growing acceptance despite societal stigma associated with mental health disorders like ADHD.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Attention-Deficit Hyperactivity Disorder by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Attention-Deficit Hyperactivity Disorder (ADHD) market in China are Shanghai Fosun Pharmaceutical, Huadong Medicine, Adlon Therapeutics, and Ignis Therapeutics. Shanghai Fosun Pharmaceutical, Huadong Medicine, and Adlon Therapeutics are identified as key domestic players involved in ADHD therapeutics, leveraging China's sizable young population and increasing ADHD awareness to expand their market presence. Ignis Therapeutics has notably acquired exclusive licensing rights for NeuroSigma's Monarch eTNS System in China, introducing advanced bioelectronic non-invasive therapies for ADHD, which supplements traditional pharmacological treatments and enhances the therapeutic options available in the Chinese market.
In addition to these domestic companies, several multinational pharmaceutical corporations also have a significant presence in the ADHD market in China, including Novartis AG, Eli Lilly and Company, Takeda Pharmaceutical, and Johnson & Johnson. These firms provide a variety of stimulant and non-stimulant medications for ADHD, contributing to a competitive and rapidly growing market projected to reach nearly $4.73 billion by 2030. The market growth is driven by increased diagnosis rates, government support, advanced therapies, and growing acceptance despite societal stigma associated with mental health disorders like ADHD.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
